Beckman Coulter, Inc. (NYSE: BEC) today announced the creation of Beckman Coulter Genomics. The new company, which combines Agencourt Bioscience and the newly acquired Cogenics, offers researchers a single genomic services resource with expanded global capabilities.
"Through the creation of Beckman Coulter Genomics, we have successfully brought together the industry's leading genomic service providers to offer our customers the highest-quality data and analysis," said Richard Creager, Ph.D., Beckman Coulter group vice president of Immunoassay, Molecular Diagnostics and Genomic Services.
Genomic researchers dedicate months to collecting DNA and RNA samples. Before turning over precious samples for analysis, they need to be able to trust that their service provider understands the research goals and will deliver a successful outcome. From classic to cutting-edge, Beckman Coulter Genomics' team has expertise and experience on a wide range of genomic technology platforms and is dedicated to delivering the highest-quality results. Services currently available through Beckman Coulter Genomics include sequencing, sample preparation, genotyping, gene expression, biological efficiency and safety testing, with support for all levels of regulatory compliance, including Clinical Laboratory Improvement Amendments (CLIA). In addition, Beckman Coulter Genomics offers all three commercially available next-generation sequencing platforms: Roche 454 Genome Sequencer FLX with Titanium, Applied Biosystems SOLiD* and Illumina* Genome Analyzer.